Disease Severity Modifier in the NICE Single Technology Appraisal of Trastuzumab Deruxtecan: External Assessment Group Perspective

Diarmuid Coughlan, Oluwatomi Arisa, Katie Thomson, Ge Yu, Fiona Pearson, Ashleigh Kernohan, Sonia Garcia Gonzalez-Moral, Sheila Wallace, Stephen Rice

Research output: Contribution to journalComment/debatepeer-review

Original languageEnglish
Pages (from-to)5-9
Number of pages5
Issue number1
Early online date5 Oct 2023
Publication statusPublished - 1 Jan 2024

Bibliographical note

Funding Information:
This project was commissioned by the National Institute for Health and Care Research (NIHR) Health Technology Assessment (HTA) Programme (Grant number: NIHR132004). See the HTA programme website for further project information ( https://www.nihr.ac.uk/explore-nihr/funding-programmes/health-technology-assessment.htm ). This summary of the EAG report was compiled after NICE issued recommendations for the Cancer Drug Fund (CDF). The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the NICE, NIHR or Department of Health and Social Care.


  • Humans
  • Trastuzumab/therapeutic use
  • Camptothecin
  • Immunoconjugates
  • Technology Assessment, Biomedical
  • Cost-Benefit Analysis
  • Receptor, ErbB-2

Cite this